Plain-English translation of NCT03474822 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing Plasmodium vivax immunotherapy, an experimental approach that deliberately gives patients a controlled, manageable parasite infection to trigger their immune system to fight cancer. Researchers believe this parasite may activate the body's natural defenses against tumors. The infection is carefully monitored and stopped after 4–6 weeks using antimalarial medication, though the immune-boosting effects may continue afterward.
Standard cancer treatments like chemotherapy and radiation don't work for everyone, and some advanced cancers become resistant to these approaches. This trial exists to explore whether activating the immune system in a new way — through this controlled parasite infection — might help patients whose cancer has not responded to conventional therapy.
You would receive an injection of blood cells infected with the parasite, which would establish a controlled infection in your body. Over the next 4–6 weeks, you would be closely monitored with regular blood tests and clinic visits to track the infection, watch for fever or other symptoms, and measure your cancer response. After 4–6 weeks, you would take antimalarial medication to stop the infection, and then you would continue in follow-up visits for 2 years to see if the immune boost helps control your cancer.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
CAS Lamvac Biotech Co., Ltd.
Enrollment target
~60 participants
Started
August 2018
Primary completion
June 2023
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qin Li, M.D
CAS Lamvac Biotech Co., Ltd.